Insider Trading February 13, 2026

Director Edilson Camara Buys $199,626 of Cleveland-Cliffs Stock Amid Recent Share Decline

19,700 shares purchased on Feb. 13, 2026 as company reports a narrower fourth-quarter adjusted loss but a revenue shortfall that prompted an analyst price-target cut

By Nina Shah CLF
Director Edilson Camara Buys $199,626 of Cleveland-Cliffs Stock Amid Recent Share Decline
CLF

Cleveland-Cliffs director Edilson Camara acquired 19,700 common shares on February 13, 2026, in a transaction valued at $199,626. The purchase occurred as the stock has fallen sharply in the prior week and followed fourth-quarter results that showed a smaller-than-expected adjusted loss per share but weaker revenue and EBITDA performance, prompting an analyst to lower the price target while keeping a Neutral rating.

Key Points

  • Director Edilson Camara purchased 19,700 Cleveland-Cliffs shares on Feb. 13, 2026 for $199,626, increasing his direct holdings to 41,983 shares - impacts corporate governance and insider ownership
  • Cleveland-Cliffs reported a narrower-than-expected fourth-quarter adjusted loss per share ($0.43 vs $0.56 expected) but missed revenue estimates ($4.31B vs $4.58B expected) - affects materials and industrial sectors
  • BofA Securities lowered its price target from $14.50 to $13.00 but kept a Neutral rating, citing an adjusted EBITDA shortfall largely due to lower shipments - relevant for equity analysts and fixed-income market participants

Director Edilson Camara completed an insider purchase of Cleveland-Cliffs INC common stock on February 13, 2026, acquiring 19,700 shares for a total outlay of $199,626. The transaction was executed at a weighted average price of $10.1333 per share, with individual trades ranging from $10.12 to $10.14.

The timing of the purchase coincides with elevated share-price volatility: the stock declined by nearly 27% over the prior week. At the time of reporting, the market price of $10.65 stands modestly above the director’s weighted average purchase price.

Following the transaction, Camara’s direct ownership in Cleveland-Cliffs totals 41,983 common shares.

Financial indicators for the company remain challenged. Over the last twelve months, Cleveland-Cliffs reported negative earnings of -$2.90 per share. Most recently, the company released fourth-quarter 2025 results showing an adjusted loss per share of $0.43, which was a narrower loss than the $0.56 expected by consensus estimates. Revenue for the quarter was $4.31 billion, however, falling short of the anticipated $4.58 billion.

Those quarterly results fed into analyst reassessments. BofA Securities reduced its price target on Cleveland-Cliffs from $14.50 to $13.00 while retaining a Neutral rating. The firm attributed the shortfall in adjusted EBITDA relative to its and consensus expectations largely to lower shipments during the period.

The combination of a director purchase, recent earnings detail and revised analyst outlook provides several strands for investors to weigh. The insider purchase represents an increase in direct shareholding by a board member, while the underlying operating results point to pressures on volumes and margins that influenced professional forecasts.


Context and implications

  • The purchase size and price range are precise: 19,700 shares at a weighted average of $10.1333, with trade prices between $10.12 and $10.14, totaling $199,626.
  • Recent reported operating metrics include a trailing twelve-month EPS of -$2.90 and a fourth-quarter adjusted EPS loss of $0.43 versus an expected $0.56, alongside a revenue miss: $4.31 billion reported versus $4.58 billion expected.
  • Analyst reaction included a price-target cut from $14.50 to $13.00 by BofA Securities, which remained Neutral and cited lower shipments as a primary driver of the EBITDA shortfall.

Risks

  • Revenue shortfall in the fourth quarter compared with expectations, which may pressure near-term margins and investor confidence - impacts the industrials and materials sectors
  • Adjusted EBITDA missed estimates because of lower shipments, highlighting demand and operational risk for the company - affects steel production and downstream manufacturing markets
  • Significant recent share-price volatility, including a nearly 27% decline over the prior week, introduces market risk for shareholders and potential liquidity considerations

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026